Loading...
•
Jun 30, 2024
Dynavax Q2 2024 Earnings Report
Reported record quarterly HEPLISAV-B® net product revenue and initiated dosing in Phase 1/2 trial of novel shingles vaccine program.
Key Takeaways
Dynavax reported a strong second quarter in 2024, marked by record HEPLISAV-B net product revenue and the initiation of a Phase 1/2 trial for its novel shingles vaccine program. The company is optimistic about the adult hepatitis B vaccine market and continues to evaluate strategic opportunities for growth.
Achieved record quarterly HEPLISAV-B® net product revenue of $70.2 million, growing 24% year-over-year.
Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million.
Initiated dosing in Phase 1/2 trial of novel shingles vaccine program with clinical data expected in 2H 2025.
HEPLISAV-B total estimated market share in the U.S. increased to approximately 42%.
Revenue by Segment
Forward Guidance
Dynavax is reiterating its full year 2024 financial guidance.
Positive Outlook
- HEPLISAV-B net product revenue between approximately $265 - $280 million, including approximately $3 million in ex-U.S. sales through commercialization partnership in Germany
- HEPLISAV-B gross margin of approximately 80%
- Research and development expenses between approximately $60 - $75 million
- Selling, general and administrative expenses between approximately $160 - $180 million
- Cash, cash equivalents and marketable securities to be higher as of December 31, 2024, compared to December 31, 2023
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...